A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) — Galileo

Myotonic Dystrophy Type 1 (DM1) Clinical Trial

Official title:
A Phase 1/2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type 1

Status Recruiting

Clinical Trial Summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06185764
Study type	Interventional
Source	Vertex Pharmaceuticals Incorporated
Contact	Medical Information
Phone	617-341-6777
Email	medicalinfo@vrtx.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	February 20, 2024
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05481879` - Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1	Phase 1/Phase 2
Completed	`NCT05027269` - Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients	Phase 1/Phase 2
Completed	`NCT04835298` - Breathlessness Assessment in Adult Patients With Myotonic Dystrophy Type 1
Completed	`NCT03589677` - Brain Involvement in Myotonic Dystrophy Type I: From Functional Neuroimaging to the Impact on Quality of Life
Recruiting	`NCT05560438` - Technology Assisted Rehabilitation for Upper Limb Function in Myotonic Dystrophy Type 1	N/A
Recruiting	`NCT05072288` - A Remote Physical Activity Program in the Population Suffering From Type 1 Myotonic Dystrophy	N/A
Completed	`NCT04907162` - Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders